| 0 | 💬 0 |
Efficacy and biomarker exploration of anlotinib plus penpulimab in second-line ES-SCLC: Results from the phase 2 ALTER-L041 trial.
(linkinghub.elsevier.com)
|
Cell Reports Medicine 2026-07-22 | #clinical trial #immunotherapy #lung cancer #biomarker #ctdna |